USE AND EFFECTIVENESS OF PLERIXAFOR FOR HEMATOPOIETIC STEM CELLS MOBILISATION
CP-008
COMPARISON OF PRESCRIPTION PROFILE OF ANTIRETROVIRALS DRUGS BETWEEN 2014 AND 2016 IN A TERTIARY CARE HOSPITAL
CP-007
MEDICATION ERRORS IN VOLUNTARY REPORTED INCIDENTS AT A UNIVERSITY HOSPITAL
CP-116
EVALUATION OF THE CLINICAL SIGNIFICANCE AND VALUE OF A CLINICAL PHARMACY SERVICE AT A TEACHING HOSPITAL
CP-055
THE CLINICAL PHARMACIST RESOLVES MEDICATION RELATED PROBLEMS IN CRANIO, MAXILLOFACIAL AND ORAL SURGERY PATIENTS
CP-085
THE IMPACT OF PHARMACIST INTERVENTIONS ON SAFETY AND COST SAVINGS
CP-235
ANALYSIS OF PHARMACIST INTERVENTIONS’ ACCEPTANCE RATE IN A TERTIARY HOSPITAL
CP-182
PHARMACEUTICAL VALIDATION OF TREATMENTS: FROM THE PHARMACY OR AT THE HOSPITAL WARDS?
CP-175
THE VALUE ADDED BY THE PHARMACIST : DRUG-DRUG INTERACTIONS ANALYSIS IN MULTIDISCIPLINARY MEETING FOR HEPATITIS C
CP-173
TOPICAL 0.1% RAPAMYCIN FOR ANGIOFIBROMAS IN A PAEDIATRIC PATIENT WITH TUBEROUS SCLEROSIS
CP-151
EFFICACY OF 4, 12 AND 24 WEEKS OF TREATMENT WITH LEDIPASVIR/SOFOSBUVIR, SIMEPREVIR, SOFOSBUVIR, SOFOSBUVIR/SIMEPREVIR AND SOFOSBUVIR/DACLATASVIR IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS
CP-147
PHARMACIST INTERVENTION AND ITS DOCUMENTATION IN THE COMPUTERISED MEDICAL RECORD IN SAP
CP-121
ANALYSIS OF THE USE OF ANTIDOTES IN A UNIVERSITY HOSPITAL
CP-110
MAXIMSING PHARMACISTS’ EFFICIENCY AND IMPROVING PATIENT CARE IN CANCER OUTPATIENT CLINICS
CP-059
EVALUATION OF TREATMENT WITH NATALIZUMAB THERAPY ON TRIPLE RISK PATIENTS REGARDING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
